iBio, Inc. (IBIO)
After hours:
| Previous close | 0.2909 |
| Open | 0.3000 |
| Bid | 0.3050 x 1100 |
| Ask | 0.3100 x 1100 |
| Day's range | 0.3000 - 0.3100 |
| 52-week range | 0.2600 - 4.5000 |
| Volume | |
| Avg. volume | 607,138 |
| Market cap | 8.373M |
| Beta (5Y monthly) | -3.16 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -149.2700 |
| Earnings date | 13 Nov 2023 - 17 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireiBio Announces Filing of 2023 Annual Report on SEC Form 10-K
BRYAN, Texas and SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today the filing of its annual report on Form 10-K with the United States Securities and Exchange Commission ("SEC") for the fiscal year ended June 30, 2023. Revenues for the fiscal year ended June 30, 2023 were $nil, compared to $1.9 million in fiscal 2022. Total operating expenses, not including the loss from d
- GlobeNewswire
iBio Announces Amendment to Credit Agreement with Woodforest
– Extends maturity date to December 31, 2023 –– Allows time to close pending sale of CDMO facility –BRYAN, Texas and SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced its wholly owned subsidiary, iBio CDMO LLC, and Woodforest National Bank (“Woodforest”) have entered into a sixth amendment (the “Amendment”) to their November 1, 2021 credit agreement (the “Credit Agreement”
- GlobeNewswire
iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development
– AI-powered technology enables rapid, simultaneous progress of antibodies against challenging targets – BRYAN, Texas and SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced positive pre-clinical in vivo data for three immuno-oncology candidates, anti-EGFRvIII, CCR8 and a bispecific TROP-2 x CD3, advancing these programs to clinical candidate selection stage. The anti-EGFRvII
